The Company has recently initiated an optimized phase 2 study with the goal of demonstrating that Foxy-5 counteracts metastasis formation and risk of recurrence in colon cancer patients.

The objective is to obtain indicative results already in Q2 2020. Positive signals during the first half of the year would give the company a strong foundation for an expansive strategy, to confidently complete the now initiated phase 2 study.